Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment.
10.3341/kjo.2014.28.2.177
- Author:
Ye Jin AHN
1
;
Hyung Bin HWANG
;
Sung Kun CHUNG
Author Information
1. Department of Ophthalmology and Visual Science, Yeouido St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea. eyedoc@catholic.ac.kr
- Publication Type:Case Reports
- Keywords:
Corneal neovascularization;
Herpetic keratitis;
Ranibizumab;
Subconjunctival and intrastromal injections
- MeSH:
Adult;
Angiogenesis Inhibitors/administration & dosage;
Antibodies, Monoclonal, Humanized/*administration & dosage;
Conjunctiva/blood supply;
Corneal Neovascularization/*drug therapy;
Corneal Stroma/blood supply;
Female;
Humans;
Injections, Intraocular/methods;
Keratitis, Herpetic/*drug therapy;
Visual Acuity/drug effects
- From:Korean Journal of Ophthalmology
2014;28(2):177-180
- CountryRepublic of Korea
- Language:English
-
Abstract:
Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunctivitis with refractory corneal NV despite two previous subconjunctival and intrastromal bevacizumab injections, received two subconjunctival and intrastromal ranibizumab injections. Six months postoperatively, there was significant regression of the neovascular area and vessel caliber. Here, the authors report a case of improvement in corneal NV with subconjunctival and intrastromal ranibizumab injections, which was previously refractory to bevacizumab injection. The findings may suggest a new prospect in treating corneal NV.
